Phase I multiple dose-escalation trial investigating the tolerability of DV 1179 in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2011
At a glance
- Drugs DV 1179 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- 20 Dec 2011 Status changed from recruiting to completed.
- 21 Apr 2011 New trial record
- 20 Apr 2011 Data are expected later in 2011, according to a Dynavax Technologies media release.